Clinical trial of an inhibitor of RAGE-Aβ interactions in Alzheimer disease

OBJECTIVE: To examine safety, tolerability, and efficacy of PF-04494700, an inhibitor of the receptor for advanced glycation end products (RAGE), in mild to moderate Alzheimer disease (AD). METHODS: Double-blind, placebo-controlled trial at 40 academic centers (United States). Subjects with AD and M...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Galasko, Douglas, Bell, Joanne, Mancuso, Jessica Y., Kupiec, James W., Sabbagh, Marwan N., van Dyck, Christopher, Thomas, Ronald G., Aisen, Paul S.
Formato: Artigo
Lenguaje:Inglês
Publicado: Lippincott Williams & Wilkins 2014
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4011464/
https://ncbi.nlm.nih.gov/pubmed/24696507
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/WNL.0000000000000364
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares